FINAL YEAR B.PHARM. SEMESTER-VII (2011 Course) :
SUMMER - 2019
SUBJECT : Dosage Form Design IV

Day : Thursday
Date : 02/05/2019
S-2019-4457
Time : 02.00 PM TO 05.00 PM
Max. Marks : 80

N.B.:

1) **Q.No.1** and **Q.No.5** are **COMPULSORY**. Out of the remaining questions attempt **ANY TWO** questions from each section.
2) Answers to both the sections should be written in **SEPARATE** answer books.
3) Draw neat and labeled diagram **WHEREVER** necessary.
4) Figures to the right indicate **FULL** marks.

SECTION – I

Q.1 Attempt **ANY FIVE** of the following: **(10)**
a) Differentiate between CDDS and Sustained release formulation.
b) Draw a neat diagram of liposome.
c) State merits of nasal DDS.
d) What are TPIS DDS?
e) Draw a neat diagram of compudose DDS.
f) Give the advantages of niosomes.
g) What is spray drying and Spray congealing?

Q.2 **a)** Discuss mechanism of release profiles in matrix DDS. **(08)**
b) Discuss microencapsulation by coacervation technique. **(07)**

Q.3 **a)** Five a detailed account on effect of polymer solubility and crystallinity in release profile of drug in CDDS. **(08)**
b) Discuss pH activated DDS. **(07)**

Q.4 Write notes on **ANY THREE:** **(15)**
a) Feed back regulated DDS.
b) Intra gastric floating DDS.
c) Microreservior DDS.
d) Nitroder and Transnitro DDS.
e) Dynamics of GI tract in development of oral DDS.

SECTION –II

Q.5 Answer **ANY FIVE** of the following: **(10)**
a) Define GMP.
b) State the difference between QC and QA.
c) Give a brief account on instability of acetaminophen.
d) Enlist various detergents used in cleaning process.
e) State the importance of Master File Records.
f) State duties of a coordinator in GLP.
g) Give the significance of TQM.

Q.6 **a)** Discuss GLP process in a pharma industry. **(08)**
b) Give a detailed account on various factors affecting stability of drug. **(07)**

Q.7 **a)** Discuss GMP in relation to equipments. **(08)**
b) Describe IPQC testing in manufacture and packaging of any finished product. **(07)**

Q.8 Write notes on (**ANY THREE**): **(15)**
a) ICH stability guidelines.
b) Mix up and cross contamination.
c) Process validation.
d) Quality Management System.
e) Documentation and its significance.

* * * * *